Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis

Cooper, 2008, Usefulness of immunosuppression for giant cell myocarditis, Am J Cardiol, 102, 1535, 10.1016/j.amjcard.2008.07.041 Cooper, 1997, Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter giant cell myocarditis study group Investigators, N Engl J Med, 336, 1860, 10.1056/NEJM199706263362603 Gries, 1992, Giant cell myocarditis: first report of disease recurrence in the transplanted heart, J Heart Lung Transplant, 11, 370 Scott, 2001, Recurrence of giant cell myocarditis in cardiac allograft, J Heart Lung Transplant, 20, 375, 10.1016/S1053-2498(00)00314-4 Okura, 2003, A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis, J Am Coll Cardiol, 41, 322, 10.1016/S0735-1097(02)02715-8 Kandolin, 2013, Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression, Circ Heart Fail, 6, 15, 10.1161/CIRCHEARTFAILURE.112.969261 From, 2011, Current status of endomyocardial biopsy, Mayo Clin Proc, 86, 1095, 10.4065/mcp.2011.0296 Bennett, 2013, Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009, Circ Heart Fail, 6, 676, 10.1161/CIRCHEARTFAILURE.112.000087 Cooper, 2007, J Am Coll Cardiol, 50, 1914, 10.1016/j.jacc.2007.09.008 Caforio, 2013, Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 34, 2636, 10.1093/eurheartj/eht210